ULTRAHUMAN Trademark

Trademark Overview

On Tuesday, February 6, 2018, a trademark application was filed for ULTRAHUMAN with the United States Patent and Trademark Office. The USPTO has given the ULTRAHUMAN trademark a serial number of 79238651. The federal status of this trademark filing is REGISTERED as of Tuesday, July 2, 2019. This trademark is owned by ULTRAHUMAN LIMITED. The ULTRAHUMAN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical drug development services, information, consultancy and advisory services relating to the aforesaid
ultrahuman

General Information

Serial Number79238651
Word MarkULTRAHUMAN
Filing DateTuesday, February 6, 2018
Status700 - REGISTERED
Status DateTuesday, July 2, 2019
Registration Number5790559
Registration DateTuesday, July 2, 2019
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 16, 2019

Trademark Statements

Description of MarkThe mark consists of the stylized wording "ULTRAHUMAN" with five shaded squares as the letter "T".
Pseudo MarkULTRA HUMAN
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesPharmaceutical drug development services, information, consultancy and advisory services relating to the aforesaid

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, August 20, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameULTRAHUMAN LIMITED
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB
Party NameULTRAHUMAN LIMITED
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB
Party NameULTRAHUMAN LIMITED
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Monday, August 20, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 16, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, August 20, 2018ASSIGNED TO EXAMINER
Thursday, September 6, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, March 4, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 23, 2018NON-FINAL ACTION WRITTEN
Friday, August 24, 2018APPLICATION FILING RECEIPT MAILED
Friday, August 24, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, September 6, 2018REFUSAL PROCESSED BY MPU
Friday, September 21, 2018REFUSAL PROCESSED BY IB
Monday, March 4, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 4, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 5, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 7, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 16, 2019PUBLISHED FOR OPPOSITION
Tuesday, April 16, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 2, 2019REGISTERED-PRINCIPAL REGISTER
Wednesday, October 2, 2019FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, October 11, 2019FINAL DISPOSITION PROCESSED
Friday, October 11, 2019FINAL DISPOSITION NOTICE SENT TO IB
Friday, November 1, 2019FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, July 10, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, July 10, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 10, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 10, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, July 10, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 10, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 2, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, August 6, 2020NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

ultrahuman services advisory relating aforesaid consultancy information drug development pharmaceutical